US Naval Research Laboratory said on Thursday that its researchers have submitted their findings about the methods in developing SARS-CoV-2 nanoparticle non-infectious probes that are used to study fundamental interactions between SARS-CoV-2 Spike proteins and human cells in partnership with National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
Filed in ACS Nano, a monthly peer-reviewed scientific journal, the manuscript is titled "Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Host Cell Surface Angiotensin Converting Enzyme 2 Binding and Endocytosis."
SARS-CoV-2 is known to attach to angiotensin converting enzyme 2 (ACE2) receptors via its external 'Spike' proteins, which cover the surface, which the virus uses to bind with and enter human cells. The scientists noticed the potency of the quantum dot nanoparticles to induce translocation of ACE2 from the cell membrane to the interior of the cell through a process called endocytosis.
Currently, the partnership is testing the feasibility of high-throughput cellular imaging tests to screen entire libraries of therapeutic agents for inhibition of Spike/ACE2 binding and internalization at NCATS, would allow for screening of up to 1,536 drug targets per experiment.
In conjunction, the company plans to investigate the mechanism that increases infectiousness of SARS-CoV-2 with mutated Spike proteins as well as use the pseudo-virions for site-specific intracellular drug delivery for purposes of disrupting SARS-CoV-2 replication mechanisms.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial